Stream the ‘Key considerations in the safety evaluation of drugs targeting immune checkpoints’ webinar today and learn:
- What is cancer immunotherapy?
- What are the potential challenges in the safety assessment of antibodies targeting immune system checkpoints?
- Things to consider when designing and running your nonclinical safety programmes for immune checkpoint targets
- How to measure immunotoxicity / immunopharmacology
- What if your chosen therapeutic has no pharmacologically relevant non-clinical safety species?
Lee Coney, Chief Scientific Officer – Biologics
Mandy Horn, Supervisor - Veterinary Science, Research and Support